Sanara MedTech (Sanara MedTech) Operating Cash Flow per Share : $-0.40 (TTM As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Sanara MedTech Operating Cash Flow per Share?

Sanara MedTech's operating cash flow per share for the three months ended in Dec. 2023 was $-0.10. Sanara MedTech's operating cash flow per share for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.40.

During the past 3 years, the average Operating Cash Flow per Share Growth Rate was 17.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the OCF Growth Rate using Operating Cash Flow per Share data.

The historical rank and industry rank for Sanara MedTech's Operating Cash Flow per Share or its related term are showing as below:

SMTI' s 3-Year OCF Growth Rate Range Over the Past 10 Years
Min: -126.6 Med: -5.8 Max: 65.3
Current: 17.7

During the past 13 years, Sanara MedTech's highest 3-Year average Operating Cash Flow per Share Growth Rate was 65.30% per year. The lowest was -126.60% per year. And the median was -5.80% per year.

SMTI's 3-Year OCF Growth Rate is ranked better than
69.3% of 684 companies
in the Medical Devices & Instruments industry
Industry Median: 3.65 vs SMTI: 17.70

Sanara MedTech Operating Cash Flow per Share Historical Data

The historical data trend for Sanara MedTech's Operating Cash Flow per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sanara MedTech Operating Cash Flow per Share Chart

Sanara MedTech Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Operating Cash Flow per Share

Get a 7-Day Free Trial

-0.61

-0.70

-0.66

-0.70

-0.39

Sanara MedTech Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Operating Cash Flow per Share	Get a 7-Day Free Trial															-0.08	-0.21	-0.21	0.13	-0.10

Competitive Comparison of Sanara MedTech's Operating Cash Flow per Share

For the Medical Instruments & Supplies subindustry, Sanara MedTech's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sanara MedTech's Price-to-Operating-Cash-Flow Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Sanara MedTech's Price-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Sanara MedTech's Price-to-Operating-Cash-Flow falls into.

Sanara MedTech Operating Cash Flow per Share Calculation

Operating Cash Flow per Share is the amount of Cash Flow from Operations per outstanding share of the company's stock.

Sanara MedTech's Operating Cash Flow per Share for the fiscal year that ended in Dec. 2023 is calculated as

Operating Cash Flow per Share (A: Dec. 2023 )	=	Cash Flow from Operations (A: Dec. 2023 )	/	Shares Outstanding (Diluted Average) (A: Dec. 2023 )
	=	-3.246	/	8.279
	=	-0.39

Sanara MedTech's Operating Cash Flow per Share for the quarter that ended in Dec. 2023 is calculated as

Operating Cash Flow per Share (Q: Dec. 2023 )	=	Cash Flow from Operations (Q: Dec. 2023 )	/	Shares Outstanding (Diluted Average) (Q: Dec. 2023 )
	=	-0.849	/	8.382
	=	-0.10

Operating Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.40

Sanara MedTech Operating Cash Flow per Share Related Terms

Thank you for viewing the detailed overview of Sanara MedTech's Operating Cash Flow per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Sanara MedTech (Sanara MedTech) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Sanara MedTech Inc (NAS:SMTI) » Definitions » Operating Cash Flow per Share

Comparable Companies

Traded in Other Exchanges

N/A

Address

1200 Summit Avenue, Suite 414, Fort Worth, TX, USA, 76102

Website

https://www.sanaramedtech.com

Sanara MedTech Inc is a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the chronic and surgical wound and skincare markets. Its portfolio of products and services allows it to deliver comprehensive wound and skincare solutions for patients in all care settings, including acute and post-acute. Its surgical wound care products are CellerateRX Surgical Activated Collagen. Its chronic wound care products are HYCOL Hydrolyzed Collagen, BIAKOS Skin and Wound Cleanser and BIAKOS Skin and Wound Gel.

Executives

Eric D Major	director	751 MILLER DRIVE SE, LEESBURG VA 20175
Zachary B. Fleming	officer: President - Surgical Div.	1200 SUMMIT AVE, SUITE 414, FORT WORTH TX 76102
Shawn M. Bowman	officer: President - Wound Care Div.	1200 SUMMIT AVE, SUITE 414, FORT WORTH TX 76102
Rebecca E Mcmahon	officer: President - R&D	1200 SUMMIT AVE, SUITE 414, FORT WORTH TX 76102
Sara N Ortwein	director	5959 LAS COLINAS BOULEVARD, IRVING TX 75039-2298
Robert Andrew Desutter	director	1200 SUMMIT AVE, SUITE 414, FORT WORTH TX 76102
Eric D Tanzberger	director	1929 ALLEN PARKWAY, HOUSTON TX 77219
Christopher A. Morrison	officer: President - Telehealth Svcs.	1200 SUMMIT AVENUE, SUITE 414, FORT WORTH TX 76102
Roszell Iii Mack	director	1200 SUMMIT AVE, SUITE 414, FORT WORTH TX 76102
Cgi Cellerate Rx, Llc	10 percent owner	C/O THE CATALYST GROUP, INC., 7500 RIALTO BLVD., BLDG. II, SUITE 220, AUSTIN TX 78735
Catalyst Rochal, Llc	10 percent owner	C/O THE CATALYST GROUP, INC., 7500 RIALTO BLVD., BLDG. II, SUITE 220, AUSTIN TX 78735
Bradley J. Gurasich	10 percent owner	C/O THE CATALYST GROUP, INC., 7500 RIALTO BLVD., BLDG. II, SUITE 220, AUSTIN TX 78735
J Michael Carmena	director, officer: Principal Executive Officer	1200 SUMMIT AVE STE 414, FORT WORTH TX 76102
Michael D. Mcneil	officer: Chief Financial Officer	1200 SUMMIT AVE, STE 414, FORT WORTH TX 76102
Catalyst Group, Inc.	10 percent owner	1375 ENCLAVE PARKWAY, HOUSTON TX 77077